Skip to main content
Premium Trial:

Request an Annual Quote

US Genomics Lands $4.5M Equity Investment from BD for Pathogen Detection Tech

NEW YORK (GenomeWeb News) – US Genomics said today that Becton Dickinson has taken a $4.5 million equity investment in the firm, and the two companies will collaborate to develop a molecular diagnostic test for infectious disease.
Under the collaboration, the companies will develop US Genomics’ DirectLinear Analysis technology for use in a test that will detect a range of pathogens based on genotype.
A test based on the DLA technology, which integrates labeling, microfluidics, and optics, could identify a pathogen and test for virulence and drug resistance in a sample within hours, as opposed to several days, US Genomics said.
The test could help doctors predict what drugs a pathogen may be resistant to, and which drugs might make the most effective treatment, the company added.
US Genomics said that it has so far invested more than $50 million in developing the DLA technology, with support from venture funding, the US Department of Homeland Security, the National Science Foundation, and the Defense Advanced Research Projects Agency.
US Genomics’ CEO, John Canepa, said in a statement that DLA’s uses include bio-security, bio-surveillance, and environmental and food safety testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.